BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lichnog C, Klabunde S, Becker E, Fuh F, Tripal P, Atreya R, Klenske E, Erickson R, Chiu H, Reed C, Chung S, Neufert C, Atreya I, McBride J, Neurath MF, Zundler S. Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease. Front Pharmacol 2019;10:39. [PMID: 30774593 DOI: 10.3389/fphar.2019.00039] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Ungar B, Malickova K, Hanžel J, Abu-Arisha M, Paul S, Rocha C, Ben-Shatach Z, Abitbol CM, Haj-Natour O, Selinger L, Yavzori M, Fudim E, Picard O, Shoval I, Eliakim R, Kopylov U, Magro F, Roblin X, Chowers Y, Drobne D, Lukas M, Ben-Horin S. Dose-optimization for loss-of-response to vedolizumab - pharmacokinetics and immune mechanisms. J Crohns Colitis 2021:jjab067. [PMID: 33837762 DOI: 10.1093/ecco-jcc/jjab067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Veny M, Garrido-Trigo A, Corraliza AM, Masamunt MC, Bassolas-Molina H, Esteller M, Arroyes M, Tristán E, Fernández-Clotet A, Ordás I, Ricart E, Esteve M, Panés J, Salas A. Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis. J Crohns Colitis 2021;15:441-52. [PMID: 32926095 DOI: 10.1093/ecco-jcc/jjaa178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Zundler S, Becker E, Schulze LL, Neurath MF. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut 2019;68:1688-700. [PMID: 31127023 DOI: 10.1136/gutjnl-2018-317977] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 18.3] [Reference Citation Analysis]
4 RoŽanc J, Finšgar M, Maver U. Progressive use of multispectral imaging flow cytometry in various research areas. Analyst 2021;146:4985-5007. [PMID: 34337638 DOI: 10.1039/d1an00788b] [Reference Citation Analysis]
5 Tong X, Zheng Y, Li Y, Xiong Y, Chen D. Soluble ligands as drug targets for treatment of inflammatory bowel disease. Pharmacol Ther 2021;226:107859. [PMID: 33895184 DOI: 10.1016/j.pharmthera.2021.107859] [Reference Citation Analysis]
6 Cox D. How not to discover a drug - integrins. Expert Opin Drug Discov 2021;16:197-211. [PMID: 32921156 DOI: 10.1080/17460441.2020.1819234] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 D'Amico F, Danese S, Peyrin-Biroulet L. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins? Expert Opin Biol Ther 2020;20:353-61. [PMID: 31951748 DOI: 10.1080/14712598.2020.1717465] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Zundler S, Wiendl M, Neurath MF. Anti-trafficking agents in the treatment of inflammatory bowel disease. Current Opinion in Gastroenterology 2019;35:499-506. [DOI: 10.1097/mog.0000000000000579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Kaplon H, Muralidharan M, Schneider Z, Reichert JM. Antibodies to watch in 2020. MAbs 2020;12:1703531. [PMID: 31847708 DOI: 10.1080/19420862.2019.1703531] [Cited by in Crossref: 219] [Cited by in F6Publishing: 193] [Article Influence: 219.0] [Reference Citation Analysis]
10 Moreno LO, Fernández-tomé S, Abalo R. Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions. Biologics 2021;1:189-210. [DOI: 10.3390/biologics1020012] [Reference Citation Analysis]
11 Carballido JM, Regairaz C, Rauld C, Raad L, Picard D, Kammüller M. The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases. Front Immunol 2020;11:472. [PMID: 32296421 DOI: 10.3389/fimmu.2020.00472] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
12 Barreto de Albuquerque J, Mueller C, Gungor B. Tissue-Resident T Cells in Chronic Relapsing-Remitting Intestinal Disorders. Cells 2021;10:1882. [PMID: 34440651 DOI: 10.3390/cells10081882] [Reference Citation Analysis]
13 Lutter L, Roosenboom B, Brand EC, Ter Linde JJ, Oldenburg B, van Lochem EG, Horje Talabur Horjus CS, van Wijk F. Homeostatic Function and Inflammatory Activation of Ileal CD8+ Tissue-Resident T Cells Is Dependent on Mucosal Location. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00137-5. [PMID: 34224909 DOI: 10.1016/j.jcmgh.2021.06.022] [Reference Citation Analysis]
14 Oftedal BE, Wolff ASB. New era of therapy for endocrine autoimmune disorders. Scand J Immunol 2020;92:e12961. [PMID: 32853446 DOI: 10.1111/sji.12961] [Reference Citation Analysis]